A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC)

Head/Neck Cancer
Jonathan Schoenfeld, MD, MPhil, MPH
Dana-Farber Cancer Institute


Adenoid cystic carcinoma (ACC) is a rare type of salivary gland tumor. Despite upfront aggressive treatment with surgery, radiation therapy, and/or chemotherapy, approximately 50% of patients develop distance metastases, and up to a third succumb to their disease within two years of diagnosis. The investigator’s data suggests that up to 70% of recurrent/metastatic ADC may initially present with oligometastatic disease (<5 metastases), and early local treatment of these oligometastatic lesions may reduce the risk of recurrence, prolong survival, and in some instances may be curative. This phase II study will assess if the early treatment of ACC patients with oligometastases utilizing stereotactic body radiotherapy (SBRT) can increase the length of time before the cancer spreads or grows compared to standard of care management. SBRT has improved the time before progression and overall survival in other cancer types.

Trial Registration: ClinicalTrials.gov Identifier: NCT04883671